Material Transfer Agreement (MTA)
Material Transfer Agreement (MTA)
Materials are typically the starting point in creating new innovations or at least play a crucial role in the process. As a result, the use of materials is potentially very valuable for generating novel intellectual property.
The Material Transfer Agreement (MTA) defines the intellectual property rights of the provider and the recipient with respect to the materials and any derivatives. Biological materials, such as reagents, cell lines, plasmids, and vectors, are the most frequently transferred materials. However, MTAs may also be used for other types of materials, such as chemical compounds and even some types of software.
Find customized MTAs for our most frequently requested materials, below, organized by the principal investigator (PI).
Instructions
Download the appropriate MTA. Complete the MTA in its entirety. Any missing information could result in delayed processing.
For foreign entities, be sure to complete both Appendix A and Appendix B of the MTA.
Once you have obtained the appropriate signature, either fax copy of the MTA to (505) 665-0154 (Attn: MTA Processing) or email a scanned copy of the MTA to mta@lanl.gov.
Available Materials (by PI)
Andrew Bradbury, PhD |
|||
|---|---|---|---|
|
Plasmids for phage display as described in Nucleic Acids Research, 2006, 34(21), e145 |
Antibody that recognizes sulfation as a post-translational modification |
Display Plasmids as described in Nucleic Acids Res 38, e22, (2010) |
Anti-M2 antibody as described inProtein Eng Des Sel 22, 189-198, (2009) |
|
Cre cells as described in Gene 70, 331-341 (1988) |
scFv plasmids The original library and derived antibodies are owned by Merrimack Pharmaceuticals, and for any commercial use of these plasmids/antibodies a commercial license must be obtained from Merrimack. |
Thermostable fluorescent proteins described in Protein Eng Des Sel 22, 313-323, (2009) |
|
Green Fluorescent Protein (GFP) Materials
LANL has teamed up with a local biotechnology company to distribute many of the GFP components. As of November 15, 2008, noncommercial entities interested in obtaining LANL's in vitro Split GFP, Superfolder GFP, or a mammalian codon-optimized version of the in vivo Split GFP plasmids need to obtain the materials through our partner, Sandia Biotech, Inc. All commercial parties interested in licensing these materials should visit LANL's GFP licensing page.
Geoffrey Waldo, PhD |
|||
|---|---|---|---|
|
Folding Reporter |
Superfolder GFP |
Insertion GFP |
|
|
Split GFP in vitro |
Split GFP in vivo |
Mammalian codon-optimized Split GFP in vivo |
|
|
DHFRi |
|||
Video
Historic, unique Manhattan Project footage from Los Alamos
In 1943, the top scientists from the United States and other nations gathered in Los Alamos, NM for the Manhattan Project. Among them was physicis...
Innovations for a secure nation
Plasma Technology for Textile Finishing Applications Gets a Boost from LANL
A new way to stay dry: APJeT is revolutionizing the textile industry with new plasma technology.
» All Innovations
